Personalized Therapies in Inflammatory Complex Disease
Status:
Recruiting
Trial end date:
2021-09-15
Target enrollment:
Participant gender:
Summary
Inflammatory diseases may display atypical features making such patients impossible to
classify. Management of these cases in daily practice cannot rely on the results of clinical
trials nor on guidelines. DNA and RNA mapping have become major tools to understand and
sometimes direct the treatment strategy in oncology. This study aims to test whether a
precise analysis of molecular pathways in inflammatory, non classified diseases, can
constitute a predictive tool of therapeutic efficiency
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Treatments:
Adalimumab Interleukin 1 Receptor Antagonist Protein Rituximab Ustekinumab